Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results-Reference-Cited by-同舟云学术

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results

Published:2018-04 Issue: Volume:38 Page:86-91
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

De Placido Sabino,Giuliano Mario,Schettini Francesco,Von Arx Claudia,Buono Giuseppe,Riccardi Ferdinando,Cianniello Daniela,Caputo Roberta,Puglisi Fabio,Bonotto Marta,Fabi Alessandra,Bilancia Domenico,Ciccarese Mariangela,Lorusso Vito,Michelotti Andrea,Bruzzese Dario,Veneziani Bianca Maria,Locci Mariavittoria,De Laurentiis Michelino,Arpino Grazia

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference27 articles.

1. SEER Cancer Statistics Review (CSR) 1975-2013 Updated September 12, 2016. Accessible at: https://seer.cancer.gov/statistics/summaries.html.

2. Clinical implications of the intrinsic molecular subtypes of breast cancer;Prat;The Breast,2015

3. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies;Puglisi;Drugs,2012

4. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: where we are now and where we are going;Schettini;Cancer Treat Rev,2016

5. Molecular portraits of human breast tumours;Perou;Nature,2000

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance;Drugs - Real World Outcomes;2024-06-16

2. A Comprehensive Review on the State of the Art of Breast Cancers in Italy;Current Medicinal Chemistry;2024-06

3. A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer;Journal of Comparative Effectiveness Research;2024-06

4. Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives;Heliyon;2024-01

5. Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study;The Breast;2023-12